NEURO-ONCOLOGY 润色咨询

NEURO-ONCOLOGY

出版年份:1999 年文章数:1439 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:6.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=902236, encodeId=55b39022364c, content=10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Wed Nov 25 17:32:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236799, encodeId=57a01236e9924, content=接受生信吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=禾子001, createdTime=Fri Aug 05 17:40:27 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801595, encodeId=e615801595c4, content=审稿速度:1.0<br>偏重的研究方向:胶质瘤;分子病理;组织病理<br>经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。<br>2020.3.4 submitted to editorial office - (under review - decision in process)<br>2020.4.1 major revision<br>2020.6.12 re-submit - (under review - decision in process)<br>2020.7.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c6b5275720, createdName=148311f3m56(暂无昵称), createdTime=Tue Jul 07 11:31:14 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202049, encodeId=3422120204939, content=有幸接收,分享下投稿进度,历时半年:<br>8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3f8108629, createdName=xiaobao111, createdTime=Sat Mar 12 20:04:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099779, encodeId=cd081099e793f, content=推荐同行评议时需要注意哪些情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099780, encodeId=e2aa1099e8095, content=什么是correspondingauthor/通讯作者?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008473, encodeId=b08410084e3e7, content=偏重的研究方向:肿瘤<br>经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220126/b1b7e77c9eda4040b0ebdfa25ebde3b5/83ab782505994b38a76b66cbb6efc6a8.jpg, createdBy=51a75550700, createdName=钱串子, createdTime=Mon Aug 16 22:04:02 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912914, encodeId=45a691291436, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Fri Jan 01 18:51:15 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590353, encodeId=10765903531d, content=版面费<span class="quote">mengying-h 2015-10-20 19:44:00 发表:<br>15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床</span>, beContent=mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI6ibAzPjyuWibicXQwoyytqZs8geMFxTj2J8FvIrtMSibFwGXicREXYahaaOWcw9icxYGDzZMWOt8gTY2A/132, createdBy=20442328394, createdName=12265418m62(暂无昵称), createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580822, encodeId=f5645808226a, content=我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。<span class="quote">132****5832暂无昵称 2019-10-25 00:00:00 发表:<br>求经验求分享</span>, beContent=132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UIzHPNHUia7IZ09cicMjBz3c1jfCVia0nibmsgicGyXzPRdNZJwjogpMxK5ZTezrSeYicbCC4gnibibtO7t8BrkUExQUWQ/132, createdBy=fc5288016, createdName=zouwei8887, createdTime=Mon Dec 02 00:00:00 CST 2019, time=2019-12-02, status=1, ipAttribution=)]
    2020-11-25 H·D·E

    10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗

    11

    展开11条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=902236, encodeId=55b39022364c, content=10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Wed Nov 25 17:32:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236799, encodeId=57a01236e9924, content=接受生信吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=禾子001, createdTime=Fri Aug 05 17:40:27 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801595, encodeId=e615801595c4, content=审稿速度:1.0<br>偏重的研究方向:胶质瘤;分子病理;组织病理<br>经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。<br>2020.3.4 submitted to editorial office - (under review - decision in process)<br>2020.4.1 major revision<br>2020.6.12 re-submit - (under review - decision in process)<br>2020.7.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c6b5275720, createdName=148311f3m56(暂无昵称), createdTime=Tue Jul 07 11:31:14 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202049, encodeId=3422120204939, content=有幸接收,分享下投稿进度,历时半年:<br>8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3f8108629, createdName=xiaobao111, createdTime=Sat Mar 12 20:04:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099779, encodeId=cd081099e793f, content=推荐同行评议时需要注意哪些情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099780, encodeId=e2aa1099e8095, content=什么是correspondingauthor/通讯作者?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008473, encodeId=b08410084e3e7, content=偏重的研究方向:肿瘤<br>经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220126/b1b7e77c9eda4040b0ebdfa25ebde3b5/83ab782505994b38a76b66cbb6efc6a8.jpg, createdBy=51a75550700, createdName=钱串子, createdTime=Mon Aug 16 22:04:02 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912914, encodeId=45a691291436, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Fri Jan 01 18:51:15 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590353, encodeId=10765903531d, content=版面费<span class="quote">mengying-h 2015-10-20 19:44:00 发表:<br>15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床</span>, beContent=mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI6ibAzPjyuWibicXQwoyytqZs8geMFxTj2J8FvIrtMSibFwGXicREXYahaaOWcw9icxYGDzZMWOt8gTY2A/132, createdBy=20442328394, createdName=12265418m62(暂无昵称), createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580822, encodeId=f5645808226a, content=我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。<span class="quote">132****5832暂无昵称 2019-10-25 00:00:00 发表:<br>求经验求分享</span>, beContent=132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UIzHPNHUia7IZ09cicMjBz3c1jfCVia0nibmsgicGyXzPRdNZJwjogpMxK5ZTezrSeYicbCC4gnibibtO7t8BrkUExQUWQ/132, createdBy=fc5288016, createdName=zouwei8887, createdTime=Mon Dec 02 00:00:00 CST 2019, time=2019-12-02, status=1, ipAttribution=)]
    2022-08-05 禾子001

    接受生信吗?

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=902236, encodeId=55b39022364c, content=10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Wed Nov 25 17:32:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236799, encodeId=57a01236e9924, content=接受生信吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=禾子001, createdTime=Fri Aug 05 17:40:27 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801595, encodeId=e615801595c4, content=审稿速度:1.0<br>偏重的研究方向:胶质瘤;分子病理;组织病理<br>经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。<br>2020.3.4 submitted to editorial office - (under review - decision in process)<br>2020.4.1 major revision<br>2020.6.12 re-submit - (under review - decision in process)<br>2020.7.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c6b5275720, createdName=148311f3m56(暂无昵称), createdTime=Tue Jul 07 11:31:14 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202049, encodeId=3422120204939, content=有幸接收,分享下投稿进度,历时半年:<br>8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3f8108629, createdName=xiaobao111, createdTime=Sat Mar 12 20:04:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099779, encodeId=cd081099e793f, content=推荐同行评议时需要注意哪些情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099780, encodeId=e2aa1099e8095, content=什么是correspondingauthor/通讯作者?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008473, encodeId=b08410084e3e7, content=偏重的研究方向:肿瘤<br>经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220126/b1b7e77c9eda4040b0ebdfa25ebde3b5/83ab782505994b38a76b66cbb6efc6a8.jpg, createdBy=51a75550700, createdName=钱串子, createdTime=Mon Aug 16 22:04:02 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912914, encodeId=45a691291436, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Fri Jan 01 18:51:15 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590353, encodeId=10765903531d, content=版面费<span class="quote">mengying-h 2015-10-20 19:44:00 发表:<br>15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床</span>, beContent=mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI6ibAzPjyuWibicXQwoyytqZs8geMFxTj2J8FvIrtMSibFwGXicREXYahaaOWcw9icxYGDzZMWOt8gTY2A/132, createdBy=20442328394, createdName=12265418m62(暂无昵称), createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580822, encodeId=f5645808226a, content=我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。<span class="quote">132****5832暂无昵称 2019-10-25 00:00:00 发表:<br>求经验求分享</span>, beContent=132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UIzHPNHUia7IZ09cicMjBz3c1jfCVia0nibmsgicGyXzPRdNZJwjogpMxK5ZTezrSeYicbCC4gnibibtO7t8BrkUExQUWQ/132, createdBy=fc5288016, createdName=zouwei8887, createdTime=Mon Dec 02 00:00:00 CST 2019, time=2019-12-02, status=1, ipAttribution=)]
    2020-07-07 148311f3m56(暂无昵称)

    审稿速度:1.0
    偏重的研究方向:胶质瘤;分子病理;组织病理
    经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。
    2020.3.4 submitted to editorial office - (under review - decision in process)
    2020.4.1 major revision
    2020.6.12 re-submit - (under review - decision in process)
    2020.7.6 accept

    6

    展开6条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=902236, encodeId=55b39022364c, content=10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Wed Nov 25 17:32:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236799, encodeId=57a01236e9924, content=接受生信吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=禾子001, createdTime=Fri Aug 05 17:40:27 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801595, encodeId=e615801595c4, content=审稿速度:1.0<br>偏重的研究方向:胶质瘤;分子病理;组织病理<br>经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。<br>2020.3.4 submitted to editorial office - (under review - decision in process)<br>2020.4.1 major revision<br>2020.6.12 re-submit - (under review - decision in process)<br>2020.7.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c6b5275720, createdName=148311f3m56(暂无昵称), createdTime=Tue Jul 07 11:31:14 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202049, encodeId=3422120204939, content=有幸接收,分享下投稿进度,历时半年:<br>8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3f8108629, createdName=xiaobao111, createdTime=Sat Mar 12 20:04:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099779, encodeId=cd081099e793f, content=推荐同行评议时需要注意哪些情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099780, encodeId=e2aa1099e8095, content=什么是correspondingauthor/通讯作者?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008473, encodeId=b08410084e3e7, content=偏重的研究方向:肿瘤<br>经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220126/b1b7e77c9eda4040b0ebdfa25ebde3b5/83ab782505994b38a76b66cbb6efc6a8.jpg, createdBy=51a75550700, createdName=钱串子, createdTime=Mon Aug 16 22:04:02 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912914, encodeId=45a691291436, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Fri Jan 01 18:51:15 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590353, encodeId=10765903531d, content=版面费<span class="quote">mengying-h 2015-10-20 19:44:00 发表:<br>15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床</span>, beContent=mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI6ibAzPjyuWibicXQwoyytqZs8geMFxTj2J8FvIrtMSibFwGXicREXYahaaOWcw9icxYGDzZMWOt8gTY2A/132, createdBy=20442328394, createdName=12265418m62(暂无昵称), createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580822, encodeId=f5645808226a, content=我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。<span class="quote">132****5832暂无昵称 2019-10-25 00:00:00 发表:<br>求经验求分享</span>, beContent=132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UIzHPNHUia7IZ09cicMjBz3c1jfCVia0nibmsgicGyXzPRdNZJwjogpMxK5ZTezrSeYicbCC4gnibibtO7t8BrkUExQUWQ/132, createdBy=fc5288016, createdName=zouwei8887, createdTime=Mon Dec 02 00:00:00 CST 2019, time=2019-12-02, status=1, ipAttribution=)]
    2022-03-12 xiaobao111

    有幸接收,分享下投稿进度,历时半年:
    8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept

    6

    展开6条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=902236, encodeId=55b39022364c, content=10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Wed Nov 25 17:32:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236799, encodeId=57a01236e9924, content=接受生信吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=禾子001, createdTime=Fri Aug 05 17:40:27 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801595, encodeId=e615801595c4, content=审稿速度:1.0<br>偏重的研究方向:胶质瘤;分子病理;组织病理<br>经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。<br>2020.3.4 submitted to editorial office - (under review - decision in process)<br>2020.4.1 major revision<br>2020.6.12 re-submit - (under review - decision in process)<br>2020.7.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c6b5275720, createdName=148311f3m56(暂无昵称), createdTime=Tue Jul 07 11:31:14 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202049, encodeId=3422120204939, content=有幸接收,分享下投稿进度,历时半年:<br>8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3f8108629, createdName=xiaobao111, createdTime=Sat Mar 12 20:04:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099779, encodeId=cd081099e793f, content=推荐同行评议时需要注意哪些情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099780, encodeId=e2aa1099e8095, content=什么是correspondingauthor/通讯作者?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008473, encodeId=b08410084e3e7, content=偏重的研究方向:肿瘤<br>经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220126/b1b7e77c9eda4040b0ebdfa25ebde3b5/83ab782505994b38a76b66cbb6efc6a8.jpg, createdBy=51a75550700, createdName=钱串子, createdTime=Mon Aug 16 22:04:02 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912914, encodeId=45a691291436, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Fri Jan 01 18:51:15 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590353, encodeId=10765903531d, content=版面费<span class="quote">mengying-h 2015-10-20 19:44:00 发表:<br>15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床</span>, beContent=mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI6ibAzPjyuWibicXQwoyytqZs8geMFxTj2J8FvIrtMSibFwGXicREXYahaaOWcw9icxYGDzZMWOt8gTY2A/132, createdBy=20442328394, createdName=12265418m62(暂无昵称), createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580822, encodeId=f5645808226a, content=我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。<span class="quote">132****5832暂无昵称 2019-10-25 00:00:00 发表:<br>求经验求分享</span>, beContent=132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UIzHPNHUia7IZ09cicMjBz3c1jfCVia0nibmsgicGyXzPRdNZJwjogpMxK5ZTezrSeYicbCC4gnibibtO7t8BrkUExQUWQ/132, createdBy=fc5288016, createdName=zouwei8887, createdTime=Mon Dec 02 00:00:00 CST 2019, time=2019-12-02, status=1, ipAttribution=)]
    2021-12-28 乌云背后的幸福线

    推荐同行评议时需要注意哪些情况?

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=902236, encodeId=55b39022364c, content=10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Wed Nov 25 17:32:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236799, encodeId=57a01236e9924, content=接受生信吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=禾子001, createdTime=Fri Aug 05 17:40:27 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801595, encodeId=e615801595c4, content=审稿速度:1.0<br>偏重的研究方向:胶质瘤;分子病理;组织病理<br>经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。<br>2020.3.4 submitted to editorial office - (under review - decision in process)<br>2020.4.1 major revision<br>2020.6.12 re-submit - (under review - decision in process)<br>2020.7.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c6b5275720, createdName=148311f3m56(暂无昵称), createdTime=Tue Jul 07 11:31:14 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202049, encodeId=3422120204939, content=有幸接收,分享下投稿进度,历时半年:<br>8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3f8108629, createdName=xiaobao111, createdTime=Sat Mar 12 20:04:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099779, encodeId=cd081099e793f, content=推荐同行评议时需要注意哪些情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099780, encodeId=e2aa1099e8095, content=什么是correspondingauthor/通讯作者?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008473, encodeId=b08410084e3e7, content=偏重的研究方向:肿瘤<br>经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220126/b1b7e77c9eda4040b0ebdfa25ebde3b5/83ab782505994b38a76b66cbb6efc6a8.jpg, createdBy=51a75550700, createdName=钱串子, createdTime=Mon Aug 16 22:04:02 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912914, encodeId=45a691291436, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Fri Jan 01 18:51:15 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590353, encodeId=10765903531d, content=版面费<span class="quote">mengying-h 2015-10-20 19:44:00 发表:<br>15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床</span>, beContent=mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI6ibAzPjyuWibicXQwoyytqZs8geMFxTj2J8FvIrtMSibFwGXicREXYahaaOWcw9icxYGDzZMWOt8gTY2A/132, createdBy=20442328394, createdName=12265418m62(暂无昵称), createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580822, encodeId=f5645808226a, content=我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。<span class="quote">132****5832暂无昵称 2019-10-25 00:00:00 发表:<br>求经验求分享</span>, beContent=132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UIzHPNHUia7IZ09cicMjBz3c1jfCVia0nibmsgicGyXzPRdNZJwjogpMxK5ZTezrSeYicbCC4gnibibtO7t8BrkUExQUWQ/132, createdBy=fc5288016, createdName=zouwei8887, createdTime=Mon Dec 02 00:00:00 CST 2019, time=2019-12-02, status=1, ipAttribution=)]
    2021-12-27 ms6000000264964247

    什么是correspondingauthor/通讯作者?

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=902236, encodeId=55b39022364c, content=10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Wed Nov 25 17:32:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236799, encodeId=57a01236e9924, content=接受生信吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=禾子001, createdTime=Fri Aug 05 17:40:27 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801595, encodeId=e615801595c4, content=审稿速度:1.0<br>偏重的研究方向:胶质瘤;分子病理;组织病理<br>经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。<br>2020.3.4 submitted to editorial office - (under review - decision in process)<br>2020.4.1 major revision<br>2020.6.12 re-submit - (under review - decision in process)<br>2020.7.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c6b5275720, createdName=148311f3m56(暂无昵称), createdTime=Tue Jul 07 11:31:14 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202049, encodeId=3422120204939, content=有幸接收,分享下投稿进度,历时半年:<br>8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3f8108629, createdName=xiaobao111, createdTime=Sat Mar 12 20:04:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099779, encodeId=cd081099e793f, content=推荐同行评议时需要注意哪些情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099780, encodeId=e2aa1099e8095, content=什么是correspondingauthor/通讯作者?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008473, encodeId=b08410084e3e7, content=偏重的研究方向:肿瘤<br>经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220126/b1b7e77c9eda4040b0ebdfa25ebde3b5/83ab782505994b38a76b66cbb6efc6a8.jpg, createdBy=51a75550700, createdName=钱串子, createdTime=Mon Aug 16 22:04:02 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912914, encodeId=45a691291436, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Fri Jan 01 18:51:15 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590353, encodeId=10765903531d, content=版面费<span class="quote">mengying-h 2015-10-20 19:44:00 发表:<br>15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床</span>, beContent=mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI6ibAzPjyuWibicXQwoyytqZs8geMFxTj2J8FvIrtMSibFwGXicREXYahaaOWcw9icxYGDzZMWOt8gTY2A/132, createdBy=20442328394, createdName=12265418m62(暂无昵称), createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580822, encodeId=f5645808226a, content=我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。<span class="quote">132****5832暂无昵称 2019-10-25 00:00:00 发表:<br>求经验求分享</span>, beContent=132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UIzHPNHUia7IZ09cicMjBz3c1jfCVia0nibmsgicGyXzPRdNZJwjogpMxK5ZTezrSeYicbCC4gnibibtO7t8BrkUExQUWQ/132, createdBy=fc5288016, createdName=zouwei8887, createdTime=Mon Dec 02 00:00:00 CST 2019, time=2019-12-02, status=1, ipAttribution=)]
    2021-08-16 钱串子

    偏重的研究方向:肿瘤
    经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=902236, encodeId=55b39022364c, content=10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Wed Nov 25 17:32:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236799, encodeId=57a01236e9924, content=接受生信吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=禾子001, createdTime=Fri Aug 05 17:40:27 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801595, encodeId=e615801595c4, content=审稿速度:1.0<br>偏重的研究方向:胶质瘤;分子病理;组织病理<br>经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。<br>2020.3.4 submitted to editorial office - (under review - decision in process)<br>2020.4.1 major revision<br>2020.6.12 re-submit - (under review - decision in process)<br>2020.7.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c6b5275720, createdName=148311f3m56(暂无昵称), createdTime=Tue Jul 07 11:31:14 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202049, encodeId=3422120204939, content=有幸接收,分享下投稿进度,历时半年:<br>8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3f8108629, createdName=xiaobao111, createdTime=Sat Mar 12 20:04:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099779, encodeId=cd081099e793f, content=推荐同行评议时需要注意哪些情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099780, encodeId=e2aa1099e8095, content=什么是correspondingauthor/通讯作者?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008473, encodeId=b08410084e3e7, content=偏重的研究方向:肿瘤<br>经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220126/b1b7e77c9eda4040b0ebdfa25ebde3b5/83ab782505994b38a76b66cbb6efc6a8.jpg, createdBy=51a75550700, createdName=钱串子, createdTime=Mon Aug 16 22:04:02 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912914, encodeId=45a691291436, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Fri Jan 01 18:51:15 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590353, encodeId=10765903531d, content=版面费<span class="quote">mengying-h 2015-10-20 19:44:00 发表:<br>15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床</span>, beContent=mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI6ibAzPjyuWibicXQwoyytqZs8geMFxTj2J8FvIrtMSibFwGXicREXYahaaOWcw9icxYGDzZMWOt8gTY2A/132, createdBy=20442328394, createdName=12265418m62(暂无昵称), createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580822, encodeId=f5645808226a, content=我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。<span class="quote">132****5832暂无昵称 2019-10-25 00:00:00 发表:<br>求经验求分享</span>, beContent=132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UIzHPNHUia7IZ09cicMjBz3c1jfCVia0nibmsgicGyXzPRdNZJwjogpMxK5ZTezrSeYicbCC4gnibibtO7t8BrkUExQUWQ/132, createdBy=fc5288016, createdName=zouwei8887, createdTime=Mon Dec 02 00:00:00 CST 2019, time=2019-12-02, status=1, ipAttribution=)]
    2021-01-01 ms1000001725003009

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=902236, encodeId=55b39022364c, content=10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Wed Nov 25 17:32:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236799, encodeId=57a01236e9924, content=接受生信吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=禾子001, createdTime=Fri Aug 05 17:40:27 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801595, encodeId=e615801595c4, content=审稿速度:1.0<br>偏重的研究方向:胶质瘤;分子病理;组织病理<br>经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。<br>2020.3.4 submitted to editorial office - (under review - decision in process)<br>2020.4.1 major revision<br>2020.6.12 re-submit - (under review - decision in process)<br>2020.7.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c6b5275720, createdName=148311f3m56(暂无昵称), createdTime=Tue Jul 07 11:31:14 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202049, encodeId=3422120204939, content=有幸接收,分享下投稿进度,历时半年:<br>8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3f8108629, createdName=xiaobao111, createdTime=Sat Mar 12 20:04:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099779, encodeId=cd081099e793f, content=推荐同行评议时需要注意哪些情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099780, encodeId=e2aa1099e8095, content=什么是correspondingauthor/通讯作者?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008473, encodeId=b08410084e3e7, content=偏重的研究方向:肿瘤<br>经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220126/b1b7e77c9eda4040b0ebdfa25ebde3b5/83ab782505994b38a76b66cbb6efc6a8.jpg, createdBy=51a75550700, createdName=钱串子, createdTime=Mon Aug 16 22:04:02 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912914, encodeId=45a691291436, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Fri Jan 01 18:51:15 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590353, encodeId=10765903531d, content=版面费<span class="quote">mengying-h 2015-10-20 19:44:00 发表:<br>15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床</span>, beContent=mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI6ibAzPjyuWibicXQwoyytqZs8geMFxTj2J8FvIrtMSibFwGXicREXYahaaOWcw9icxYGDzZMWOt8gTY2A/132, createdBy=20442328394, createdName=12265418m62(暂无昵称), createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580822, encodeId=f5645808226a, content=我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。<span class="quote">132****5832暂无昵称 2019-10-25 00:00:00 发表:<br>求经验求分享</span>, beContent=132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UIzHPNHUia7IZ09cicMjBz3c1jfCVia0nibmsgicGyXzPRdNZJwjogpMxK5ZTezrSeYicbCC4gnibibtO7t8BrkUExQUWQ/132, createdBy=fc5288016, createdName=zouwei8887, createdTime=Mon Dec 02 00:00:00 CST 2019, time=2019-12-02, status=1, ipAttribution=)]
    2020-05-06 12265418m62(暂无昵称)

    版面费mengying-h 2015-10-20 19:44:00 发表:
    15.5.19 submit
    15.6.12 major revision
    15.9.4 re-submit
    15.9.22 conditionally accept with minor revision
    15.9.30 re-re-submit
    10.19 accept

    偏临床

    mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit
    15.6.12 major revision
    15.9.4 re-submit
    15.9.22 conditionally accept with minor revision
    15.9.30 re-re-submit
    10.19 accept

    偏临床

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=902236, encodeId=55b39022364c, content=10.31投稿,11.1with editor,11.2 under review,11.13 decision in process,一直到现在。编辑部决定时间比外审时间还长了,有谁知道是什么情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Wed Nov 25 17:32:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236799, encodeId=57a01236e9924, content=接受生信吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cba95534093, createdName=禾子001, createdTime=Fri Aug 05 17:40:27 CST 2022, time=2022-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801595, encodeId=e615801595c4, content=审稿速度:1.0<br>偏重的研究方向:胶质瘤;分子病理;组织病理<br>经验分享:与大家分享一下投稿进度,总的来说审稿是快的,一审二审都在一个月内。很幸运三位审稿人意见一致,大修补实验用了两个月。从投稿到接收一共是四个月。<br>2020.3.4 submitted to editorial office - (under review - decision in process)<br>2020.4.1 major revision<br>2020.6.12 re-submit - (under review - decision in process)<br>2020.7.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c6b5275720, createdName=148311f3m56(暂无昵称), createdTime=Tue Jul 07 11:31:14 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202049, encodeId=3422120204939, content=有幸接收,分享下投稿进度,历时半年:<br>8-2 send to journal 9-2 major revision 12-5 resubmit 1-21 minor revision 2-4 resubmit 2-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3f8108629, createdName=xiaobao111, createdTime=Sat Mar 12 20:04:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099779, encodeId=cd081099e793f, content=推荐同行评议时需要注意哪些情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099780, encodeId=e2aa1099e8095, content=什么是correspondingauthor/通讯作者?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008473, encodeId=b08410084e3e7, content=偏重的研究方向:肿瘤<br>经验分享:请问一下对meta分析友好吗?然后能共同通讯作者和共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220126/b1b7e77c9eda4040b0ebdfa25ebde3b5/83ab782505994b38a76b66cbb6efc6a8.jpg, createdBy=51a75550700, createdName=钱串子, createdTime=Mon Aug 16 22:04:02 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912914, encodeId=45a691291436, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:能不能告诉我我with editor 5天了还没有改变状态 我看你们under review好快啊 我不希望我凉啊 我很希望能中这一篇的啊 保佑我被送外审吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fa55396980, createdName=ms1000001725003009, createdTime=Fri Jan 01 18:51:15 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590353, encodeId=10765903531d, content=版面费<span class="quote">mengying-h 2015-10-20 19:44:00 发表:<br>15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床</span>, beContent=mengying-h 2015-10-20 19:44:00 发表: 15.5.19 submit <br> 15.6.12 major revision <br> 15.9.4 re-submit <br> 15.9.22 conditionally accept with minor revision <br> 15.9.30 re-re-submit <br> 10.19 accept <br> <br> 偏临床, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI6ibAzPjyuWibicXQwoyytqZs8geMFxTj2J8FvIrtMSibFwGXicREXYahaaOWcw9icxYGDzZMWOt8gTY2A/132, createdBy=20442328394, createdName=12265418m62(暂无昵称), createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580822, encodeId=f5645808226a, content=我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。<span class="quote">132****5832暂无昵称 2019-10-25 00:00:00 发表:<br>求经验求分享</span>, beContent=132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UIzHPNHUia7IZ09cicMjBz3c1jfCVia0nibmsgicGyXzPRdNZJwjogpMxK5ZTezrSeYicbCC4gnibibtO7t8BrkUExQUWQ/132, createdBy=fc5288016, createdName=zouwei8887, createdTime=Mon Dec 02 00:00:00 CST 2019, time=2019-12-02, status=1, ipAttribution=)]
    2019-12-02 zouwei8887

    我投过一篇 一审21天被拒 三个审稿人 要求很高甚至有点吹毛求疵 这种牛刊 命中还是很难呀。132****5832暂无昵称 2019-10-25 00:00:00 发表:
    求经验求分享

    132****5832暂无昵称 2019-10-25 00:00:00 发表: 求经验求分享

    0

共53条页码: 1/6页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分